



## **ASX Announcement Completion of \$1,000,000 Private Placement**

**Melbourne, 30 August 2013.** On 21 August 2013, Consegna Group Limited (Company) announced a private placement of 25,000,000 fully paid ordinary shares in the Company (Shares) at \$0.04 per Share to sophisticated investors and/or clients of Peloton Capital to raise \$1,000,000.

The Company confirms the completion of the private placement and the issue of 25,000,000 Shares. Of the 25,000,000 Shares issued, 19,043,065 Shares were issued pursuant to ASX Listing Rule 7.1 and 5,956,935 were issued pursuant to ASX Listing Rule 7.1A. An Appendix 3B in regards to the issue of Shares was lodged with ASX on 29 August 2013.

In accordance with ASX Listing Rule 3.10.5A the following information is provided to the ASX in relation to the issue of 5,956,935 Shares pursuant to ASX Listing Rule 7.1A.

1. The issue of 5,956,935 Shares pursuant to ASX Listing Rule 7.1A raised \$238,277 and diluted the voting power of existing shareholders by 0.93%.
2. Consegna elected to issue the Shares as a placement under Listing Rule 7.1A rather than a pro rata issue (or other type of issue) due to the strong support from sophisticated investors and the cost and timing benefits of a private placement.
3. There were no underwriting agreements in connection with the issue.
4. The Company incurred a broker commission fee equal to 6% of funds raised.

### **Media Enquiries**

Michael Johnson  
CEO & Executive Director  
+61 (03) 9614 3663  
[mjohnson@consegna.com](mailto:mjohnson@consegna.com)  
twitter @michaelconsegna  
[www.consegna.com](http://www.consegna.com)





## About Consegna Group Limited (ASX:CGP)

Consegna Group Limited is a Melbourne based medical technology firm with a focus on nasal, respiratory management and drug delivery technologies.

Consegna is commercializing the BreatheAssist™ technology portfolio; an intra-nasal technology designed for the global consumer and medical health markets. The BreatheAssist technology features a device capable of dilating the nostrils and/or providing a platform for a range of bioactive ingredients. The company will be commercialising the technology in multiple applications targeting:

### **Consumer Markets**

Sport + Exercise Performance  
Snoring Management

### **Clinical Programs**

Olfactory/Weight Management  
Sleep Apnea  
Drug Delivery